Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Take a look at the 1-year chart of Dynavax (NASDAQ: DVAX) below with added notations:
DVAX has been trading sideways over the past couple of months. While in the sideways range, the stock has formed a support area at $16 (green), and a level of resistance at $18 (red). At some point, the stock will have to break out of the current trading range.
The Tale of the Tape: DVAX is trading within a sideways range. The possible long positions on the stock would be either on a pullback to the $16 level, or on a break above $18. The ideal short opportunity would be on a break below $16.
Before making any trading decision, decide which side of the trade you believe gives you the highest probability of success. Do you prefer the short side of the market, long side, or do you want to be in the market at all? If you haven’t thought about it, review the overall indices themselves. For example, take a look at the S&P 500. Is it trending higher or lower? Has it recently broken through a key resistance or support level? Making these decisions ahead of time will help you decide which side of the trade you believe gives you the best opportunities.
No matter what your strategy or when you decide to enter, always remember to use protective stops and you’ll be around for the next trade. Capital preservation is always key!
Christian Tharp, CMT